Earlier this year, I attended a healthcare conference at MIT’s business school. At the end of a panel discussion about data analysis in drug discovery and development, an audience member stood up and asked whether the companies represented on the panel were analyzing genomic data for a wide range of ethnicities and subpopulations. The experts […]

Read More